Ivermectin and Mebendazole: Why These Repurposed Medications Are Being Studied in Cancer
Interest in repurposed medications has grown as patients, clinicians, and researchers look for affordable therapies that may influence multiple pathways involved in cancer growth, metabolism, immune function, and treatment resistance.
Ivermectin and mebendazole are two established human medications receiving attention in this area. Both have extensive histories of use for parasitic infections, known pharmacology, relatively low cost, and substantial preclinical research demonstrating potential anticancer activity.
Neither medication was originally developed for cancer. However, research suggests their biological activity may extend well beyond their antiparasitic effects.
Why Repurposing These Medications Makes Sense
Developing a new cancer drug can take many years and require enormous financial investment. Repurposing begins with medications that already have human-use histories and known pharmacologic characteristics.
Ivermectin and mebendazole are attractive research candidates because they:
Are approved for human use
Have extensive clinical-use histories
Are widely available and relatively inexpensive
Have known pharmacology and established dosing for approved conditions
Affect multiple pathways involved in cancer biology
Have demonstrated activity across numerous cancer models
May have value in combination with other therapies
Deserve further evaluation in well-designed human trials
The fact that a medication is inexpensive and generic should not make its biological effects less worthy of serious investigation.
Ivermectin’s Human Safety History
Ivermectin has been used in human medicine since the 1980s. Approximately 3.7 billion doses were distributed globally through mass-administration programs during a 30-year period.
Clinical research has generally found ivermectin to be well tolerated when appropriately prescribed. A controlled dose-escalation study found no indication of central nervous system toxicity at single doses as high as ten times the standard FDA-approved antiparasitic dose, although this does not establish the safety of prolonged high-dose cancer protocols.
This extensive human-use record provides researchers with considerably more safety and pharmacology information than would be available for an entirely new compound.
How Ivermectin May Influence Cancer Biology
Research suggests that ivermectin may influence multiple mechanisms involved in cancer development and progression, including:
WNT/β-catenin signaling
PI3K/Akt/mTOR signaling
PAK1 activity
Mitochondrial function
Oxidative stress
Apoptosis, or programmed cell death
Autophagy
Angiogenesis
Cancer stem-like cells
Drug-resistance transporters
Immune response within the tumor environment
Studies involving breast, ovarian, colorectal, and other cancer models have reported anticancer effects at laboratory concentrations described by researchers as potentially clinically feasible.
A 2026 prospective observational cohort involving ivermectin and mebendazole reported high rates of self-reported clinical benefit and generally favorable tolerability. Many participants were also using conventional treatments, supplements, and dietary changes, so the findings cannot determine which intervention produced the outcomes. However, they provide real-world observations that support the need for controlled clinical research.
A University of Florida phase 2 trial has also been registered to study ivermectin with immune-checkpoint therapy in adults with solid tumors, reflecting continued institutional interest in evaluating its potential role in oncology.
Mebendazole’s Human Safety History
Mebendazole is a human benzimidazole medication used to treat parasitic infections. Unlike fenbendazole, mebendazole is formulated and approved for human use.
It has several characteristics considered desirable in a repurposed medication, including:
A long record of human use
A generally well-characterized safety profile
Low cost
Oral administration
Known pharmacology
The ability to reach biologically relevant concentrations
Activity involving several cancer-related pathways
Published reviews describe mebendazole as a strong candidate for oncology repurposing because of its toxicity profile, accessibility, pharmacokinetics, and broad preclinical activity.
The safety of standard antiparasitic use does not automatically establish the safety of higher-dose, prolonged, or combination oncology use. Dosing, treatment duration, liver function, blood counts, and medication interactions still require individual consideration.
How Mebendazole May Influence Cancer Biology
Mebendazole appears to affect cancer through several potential mechanisms.
Microtubule Disruption
Mebendazole interferes with tubulin polymerization and microtubule formation. Microtubules are essential for cell division, making them an established target of several conventional chemotherapy drugs.
Preclinical lung-cancer research found that mebendazole caused mitotic arrest, abnormal spindle formation, and cancer-cell death through apoptosis.
Cancer Stem Cells and Treatment Resistance
Cancer stem-like cells may contribute to recurrence, metastatic spread, and resistance to treatment. Research suggests mebendazole may affect these populations and several pathways involved in treatment resistance.
Angiogenesis
Tumors need a blood supply to grow. Mebendazole has demonstrated anti-angiogenic activity in preclinical research, meaning it may interfere with signals involved in the development of tumor-supporting blood vessels.
Apoptosis and Cancer-Cell Growth
Studies involving lung, breast, colon, ovarian, brain, and other cancer models have reported inhibition of cancer-cell growth and induction of programmed cell death.
Potential Treatment Synergy
Preclinical studies suggest that mebendazole may work synergistically with certain chemotherapy agents and radiation. This does not establish the safety of every combination, but it supports research into mebendazole as a possible adjunct rather than viewing it only as a replacement for other care.
What Makes the Evidence Significant?
The evidence is not limited to a single laboratory experiment.
Across the published literature, researchers have reported:
Activity in multiple cancer-cell lines
Anticancer effects in animal models
Effects on multiple cancer-related pathways
Potential activity against cancer stem-like cells
Possible synergy with chemotherapy and radiation
Established human-use histories for both medications
Early human and observational data
Continued interest in clinical investigation
A 2026 review of antiparasitic medications in oncology described compelling anticancer properties across a broad range of preclinical models while recognizing the need for adequately powered clinical trials.
It is accurate to describe the evidence as substantial and promising. It is also important to distinguish this from definitive proof of improved survival or tumor control in randomized human trials.
Both statements can be true.
Why Monitoring Still Matters
A favorable safety history does not mean that every dose, duration, combination, or patient situation carries the same risk.
Important considerations may include:
Liver and kidney function
Current chemotherapy, immunotherapy, or targeted therapy
Other prescription medications
Supplement use
Potential CYP enzyme or drug-transporter interactions
Neurologic history
Blood counts
Gastrointestinal tolerance
Duration and cumulative exposure
Monitoring is not evidence that a medication is inherently dangerous. It is part of responsible individualized care—particularly when medications are used outside their approved indications or combined with other therapies.
Patients Deserve Access to the Full Conversation
People navigating cancer should not be mocked or dismissed for asking about ivermectin, mebendazole, or other repurposed medications.
They deserve an honest discussion that includes:
The strength of the mechanistic and preclinical evidence
Existing human-use and safety information
Emerging observational or clinical data
What remains unknown
Cancer-specific relevance
Potential interactions
Appropriate monitoring
The person’s goals and available options
There is a meaningful difference between making an unsupported promise and acknowledging a therapy’s legitimate scientific potential.
The Bottom Line
Ivermectin and mebendazole are established human medications with extensive clinical-use histories and substantial bodies of preclinical anticancer research.
Their proposed activity is biologically plausible, multi-targeted, and supported across numerous laboratory and animal models. Early human observations and active clinical interest strengthen the argument that these medications deserve serious, well-funded investigation.
They should not be marketed as guaranteed cures. They also should not be dismissed as having “no evidence.”
Patients deserve accurate information, appropriate monitoring, respectful collaboration, and the freedom to make informed decisions about the options they wish to explore.
Need Help Understanding the Research?
RootedWellness provides individualized education and advocacy for people interested in metabolic, integrative, repurposed, and emerging approaches.
Support may include research review, interaction considerations, laboratory-monitoring questions, preparation for medical appointments, and coordination with independent licensed clinicians when appropriate.
[Schedule a Cancer Support Strategy Session]
References and Further Reading
Why Repurposed Medications Deserve a Place in the Cancer Conversation
When someone is navigating cancer—especially an advanced diagnosis, limited treatment options, treatment delays, or disease that has not responded as hoped—it is understandable to explore every reasonable avenue.
Repurposed medications are increasingly part of that conversation. These are existing medications being researched or used for a purpose different from the one for which they were originally developed.
This is not a new or unusual concept. Drug repurposing is an established area of medical research and has contributed to treatment advances across multiple areas of medicine.
Why Study Existing Medications?
A medication developed for one condition may also influence biological pathways involved in another.
Researchers may discover that an existing medication affects:
Cancer-cell growth and division
Glucose or energy metabolism
Mitochondrial function
Inflammation
Immune signaling
Angiogenesis, or the formation of new blood vessels
Cancer stem-cell activity
Treatment resistance
Cell-death pathways
The tumor microenvironment
When these effects are identified, researchers may begin studying whether the medication could have a role beyond its original purpose.
Advantages of Repurposed Medications
Many repurposed medications have already been used in humans for years or even decades. Their general pharmacology, common side effects, and many medication interactions may be better understood than those of an entirely new compound.
Other potential advantages include:
Existing human-use history
Greater availability
Lower cost
Established manufacturing processes
Known pharmacology
The potential to affect multiple biological pathways
The possibility of being used alongside other therapies
None of this automatically proves that a medication will be effective against cancer. It does mean the medication may deserve thoughtful investigation rather than automatic dismissal.
Why Isn’t Every Promising Medication Studied in Large Trials?
Large clinical trials require significant funding, infrastructure, time, and regulatory support.
When a medication is inexpensive, generic, and no longer protected by a patent, the financial incentive for a pharmaceutical company to fund large trials may be lower. This does not prove that an inexpensive medication works, but it can help explain why promising research does not always move quickly into large human trials.
Limited clinical evidence may reflect several realities:
The research is still early
Funding is unavailable
The medication is generic or off-patent
Researchers have not established the best dose or combination
The compound may be difficult to formulate or deliver
Patient populations and cancer types are highly variable
A large clinical trial has not yet been organized
A lack of large trials should not be misrepresented as proof of effectiveness. It also should not automatically be treated as proof that an approach has no value.
Different Types of Evidence Still Matter
Randomized controlled trials are important, but they are not where scientific investigation begins.
Research may include:
Mechanistic studies
Cancer-cell studies
Animal studies
Pharmacokinetic research
Case reports
Observational studies
Early-phase human trials
Randomized controlled trials
Each type of evidence answers different questions.
Laboratory research can identify a potential mechanism. Animal research may provide additional information about biological effects. Case reports can identify unexpected outcomes or safety concerns. Observational studies can reveal patterns worth investigating. Clinical trials help determine whether an approach is safe and effective in a defined group of people.
Early evidence should be understood for what it is: a reason for further investigation—not a guarantee and not something that must be ignored until the final stage of research is complete.
Patients Deserve an Honest Conversation
People exploring repurposed medications are often told that there is “no evidence” when what may actually exist is preclinical, observational, mechanistic, or early clinical evidence.
That distinction matters.
A more accurate conversation would address:
What research currently exists
What the research suggests
What remains unknown
Whether the findings are specific to the person’s cancer type
Whether relevant concentrations can be achieved in humans
What human-safety information is available
Potential medication and treatment interactions
Appropriate laboratory monitoring
How response or progression will be evaluated
Patients should be able to ask these questions without being mocked, dismissed, or pressured.
Repurposed Does Not Have to Mean “Instead Of”
Exploring repurposed medications does not automatically mean rejecting oncology care.
Some people explore these options alongside surgery, chemotherapy, radiation, immunotherapy, or targeted therapy. Others begin researching them after conventional options have been exhausted, poorly tolerated, delayed, or declined according to their personal goals.
The decision is individual. The important point is that the person understands the available information, uncertainties, potential risks, monitoring needs, and alternatives.
Informed Choice Includes Safety
Supporting medical freedom does not mean ignoring safety.
A thoughtful approach considers:
Current medications and treatments
Liver and kidney function
Possible overlapping toxicities
Medication and supplement interactions
Baseline laboratory findings
Product quality and sourcing
Symptoms that require evaluation
Appropriate follow-up testing
The person’s diagnosis, goals, and available options
Open communication is particularly important. If a person is using a repurposed medication or investigational compound, relevant healthcare providers should have accurate information so that abnormal symptoms or laboratory findings can be evaluated appropriately.
The Bottom Line
Repurposed medications deserve a place in the cancer conversation.
They should not be promoted as guaranteed cures, but they also should not be dismissed simply because they are inexpensive, unfamiliar in oncology, or not yet supported by large randomized trials.
Patients deserve access to the available research, a clear explanation of its strengths and limitations, appropriate safety considerations, and the freedom to make informed decisions consistent with their values and goals.
The conversation should be based on evidence, transparency, respect, and patient autonomy—not fear, ridicule, or gatekeeping.
Need Help Reviewing Your Options?
RootedWellness provides individualized education and advocacy for people exploring metabolic, integrative, repurposed, and emerging approaches.
Support may include research review, supplement and medication interaction considerations, laboratory-monitoring questions, preparation for medical appointments, and coordination with independent licensed clinicians when appropriate.
RootedWellness does not prescribe medication or guarantee that a particular therapy will be prescribed.
[Schedule a Cancer Support Strategy Session]
Further Reading
Understanding the Metabolic Approach to Cancer Support
When people hear “metabolic approach,” they often assume it means following a strict ketogenic diet or eliminating every source of sugar. In reality, metabolic cancer support is much broader and should be individualized.
Cancer is not one disease, and every person’s nutritional needs, treatment plan, metabolic health, and ability to maintain weight are different. A metabolic approach looks at the internal environment surrounding the disease while continuing to address the cancer itself through the person’s chosen medical care.
What Does “Metabolic” Mean?
Metabolism describes how the body produces and uses energy. Cancer cells can alter the way they obtain energy, respond to nutrients, and interact with surrounding tissues.
The well-known Warburg effect describes the tendency of many cancer cells to rely heavily on glucose fermentation, even when oxygen is available. However, cancer metabolism is complex. Tumors can adapt and may use glucose, amino acids, fats, and other fuel sources depending on the cancer type and surrounding environment.
This means metabolic support is not simply about “starving cancer.” It involves improving the health of the person while considering factors that may influence inflammation, insulin signaling, energy production, immune function, and treatment tolerance.
Areas We May Consider
An individualized metabolic wellness plan may address:
Blood glucose and insulin regulation
Food quality and nutrient density
Adequate protein intake
Maintenance of muscle and strength
Digestive function and nutrient absorption
Inflammation and oxidative stress
Mitochondrial and cellular health
Sleep and circadian rhythm
Movement and resistance exercise
Stress and nervous-system regulation
Environmental exposures
Alcohol, tobacco, and highly processed foods
Supplements, medications, and potential interactions
The purpose is not to create an exhausting list of rules. It is to identify the areas most relevant to the individual and prioritize them appropriately.
Nutrition Must Be Individualized
Some people may benefit from reducing refined carbohydrates, added sugar, and highly processed foods. Others may need a more intentional lower-carbohydrate or ketogenic approach under appropriate supervision.
However, aggressive carbohydrate restriction, prolonged fasting, or rapid weight loss is not appropriate for everyone.
People experiencing unintended weight loss, poor appetite, difficulty swallowing, pancreatic insufficiency, digestive complications, or cancer-related muscle loss may need additional calories and protein. During treatment, maintaining strength, lean body mass, and adequate nutritional intake may be more urgent than achieving a particular glucose or ketone number.
The National Cancer Institute notes that people with cancer may require additional protein and calories to maintain strength, prevent malnutrition, and preserve quality of life.
Muscle Is Metabolically Important
Maintaining muscle is not merely a fitness goal. Muscle supports mobility, glucose regulation, physical independence, treatment tolerance, recovery, and overall resilience.
When appropriate, a metabolic-support plan may include:
Adequate daily protein
Walking and regular movement
Resistance or strength exercises
Physical therapy when needed
Monitoring weight and muscle loss
Supplementation such as a clean Bone Broth protein powder and Creatine
Addressing nausea, appetite loss, diarrhea, or other barriers to eating
The American Cancer Society recommends early nutrition screening and emphasizes preserving or increasing muscle through nutrition and physical activity when appropriate.
Metabolic Support Is Not One Protocol
A person with stable weight, insulin resistance, and a strong appetite will have different needs than someone who is underweight, losing muscle, struggling to eat, or experiencing treatment-related digestive problems.
An individualized plan should consider:
Cancer type and stage
Current and planned treatment
Medications and supplements
Weight and recent weight changes
Appetite and digestive function
Kidney and liver function
Glucose and insulin patterns
Laboratory findings
Activity level and physical limitations
Personal goals and quality of life
The Bottom Line
A metabolic approach is not about blaming someone for their diagnosis or promising that food alone can control cancer.
It is about supporting the whole person by improving metabolic health, preserving strength, addressing nutritional needs, and creating an internal environment that supports resilience and quality of life.
Need Personalized Support?
If you are navigating cancer and want help developing an individualized metabolic and integrative wellness plan, schedule a Cancer Support Strategy Session.
[Schedule a Cancer Support Strategy Session]